Comparison · NCT01097642-ce906f11
Ixabepilone vs Ixabepilone Plus Cetuximab: Recurrence Free Survival (RFS)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Ixabepilone vs Ixabepilone Plus Cetuximab: Recurrence Free Survival (RFS). Trial comparisons, record NCT01097642-ce906f11. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01097642-ce906f11
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.6 | 0.357 | 0.802 | wilson | |
| Risk in group 2 | 0.68 | 0.484 | 0.828 | wilson | |
| Risk difference, group 1 minus group 2 | -0.08 | -0.364 | 0.201 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.882 | 0.539 | 1.44 | log | |
| Odds ratio, group 1 over group 2 | 0.706 | 0.186 | 2.67 | log | |
| Number needed to treat, for one fewer participant with the outcome on Ixabepilone than on Ixabepilone Plus Cetuximab | 12.5 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Ixabepilone | Brand name is Ixempra ®; it is an epothilone B analog used in combination with other chemotherapeutics against cancer.~Ixabepilone: Ixabepilone will be given at 40mg/m\^2 IV over 180 minutes on day 1 of each of four 21 day cycles. | 9 | 15 | OG000 |
| Group 2 | Ixabepilone Plus Cetuximab | Cetuximab, brand name Erbitux, is an epidermal growth factor receptor (EGFR) inhibitor and monoclonal antibody used with Ixabepilone against cancer.~Cetuximab: Cetuximab will be given at 400mg/m\^2 IV over 120 minutes for its initial loading dose on day 1 of the first of four 21 day cycles. It will then be administered on a weekly basis at 250 mg/m\^2 IV over 60 minutes.~Ixabepilone: Ixabepilone will be given at 40mg/m\^2 IV over 180 minutes on day 1 of each of four 21 day cycles. | 17 | 25 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Recurrence Free Survival (RFS)
- Description
The secondary objective is to evaluate the RFS in both treatment groups. The criteria used: Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR., or similar definition that is accurate and appropriate.
- Time frame
- Median 3-year
- Population
Source ClinicalTrials.gov
Trial
- Title
- Neo-Adjuvant Study in Triple Negative Breast Cancer Patients
- NCT number
- NCT01097642
- Phases
- PHASE2
- Conditions
- Breast Cancer
- Interventions
- Cetuximab, Ixabepilone
- Lead sponsor
- The Methodist Hospital Research Institute
- Results first posted
- 2021-08-10
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01097642?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01097642-ce906f11